Document is current
Any future updates will be listed below
-
Authors
Tate, Ashley E.
Akingbuwa, Wonuola A. https://orcid.org/0000-0002-8205-0807
Karlsson, Robert https://orcid.org/0000-0002-8949-2587
Hottenga, Jouke-Jan https://orcid.org/0000-0002-5668-2368
Pool, René https://orcid.org/0000-0001-5579-0933
Boman, Magnus https://orcid.org/0000-0001-7949-1815
Larsson, Henrik https://orcid.org/0000-0002-6851-3297
Lundström, Sebastian https://orcid.org/0000-0001-7235-8499
Lichtenstein, Paul https://orcid.org/0000-0003-3037-5287
Middeldorp, Christel M. https://orcid.org/0000-0002-6218-0428
Bartels, Meike https://orcid.org/0000-0002-9667-7555
Kuja-Halkola, Ralf https://orcid.org/0000-0002-3765-2067
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (721567, 721567)
ERC Consolidator Grant
- License Information
-
More Information
Article History
Received: 1 April 2022
Revised: 24 October 2022
Accepted: 28 October 2022
First Online: 21 November 2022
COMPETING INTERESTS
: HL reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. All other authors report no conflicts of interest.
: The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
